These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9742289)

  • 81. Stable isotope coadministration methodology for the estimation of the fraction of imipramine metabolized to desipramine.
    Sasaki Y; Shinohara Y; Baba S
    J Pharm Sci; 1990 Feb; 79(2):96-8. PubMed ID: 2324970
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Imipramine metabolites in blood of patients during therapy and after overdose.
    Gram LF; Bjerre M; Kragh-Sørensen P; Kvinesdal B; Molin J; Pedersen OL; Reisby N
    Clin Pharmacol Ther; 1983 Mar; 33(3):335-42. PubMed ID: 6825388
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Imipramine and desipramine in plasma and spinal fluid: relationship to clinical response and serotonin metabolism.
    Muscettola G; Goodwin FK; Potter WZ; Claeys MM; Markey SP
    Arch Gen Psychiatry; 1978 May; 35(5):621-5. PubMed ID: 365126
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Correlation between plasma and cerebrospinal levels of imipramine.
    Sathananthan GL; Gershon S; Almeida M; Spector N; Spector S
    Arch Gen Psychiatry; 1976 Sep; 33(9):1109-10. PubMed ID: 962493
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Plasma levels of imipramine and desipramine in man after different routes of administration.
    Nagy A; Johansson R
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 290(2-3):145-60. PubMed ID: 1102994
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Spectroscopic analysis of charge transfer complex formation and peroxidase inhibition with tricyclic antidepressant drugs: potential anti-thyroid action.
    Rousseau A; Comby F; Buxeraud J; Raby C
    Biol Pharm Bull; 1996 May; 19(5):726-8. PubMed ID: 8741583
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
    Brøsen K; Gram LF; Klysner R; Bech P
    Eur J Clin Pharmacol; 1986; 30(1):43-9. PubMed ID: 3709631
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Drug-related alopecia in patients treated with tricyclic antidepressants.
    Warnock JK; Sieg K; Willsie D; Stevenson EK; Kestenbaum T
    J Nerv Ment Dis; 1991 Jul; 179(7):441-2. PubMed ID: 1869875
    [No Abstract]   [Full Text] [Related]  

  • 89. Model for the kinetics of imipramine and its metabolites in adolescents.
    Dell RB; Hein K; Ramakrishnan R; Puig-Antich J; Cooper T
    Ther Drug Monit; 1990 Sep; 12(5):450-9. PubMed ID: 2293407
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacokinetics of imipramine in narcoleptic horses.
    Peck KE; Hines MT; Mealey KL; Mealey RH
    Am J Vet Res; 2001 May; 62(5):783-6. PubMed ID: 11341404
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Imipramine in adolescent major depression: plasma level and clinical response.
    Ryan ND; Puig-Antich J; Cooper T; Rabinovich H; Ambrosini P; Davies M; King J; Torres D; Fried J
    Acta Psychiatr Scand; 1986 Mar; 73(3):275-88. PubMed ID: 3716845
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Imipramine-flupenthixol decanoate interaction.
    Cook PE; Dermer SW; Cardamone J
    Can J Psychiatry; 1986 Apr; 31(3):235-7. PubMed ID: 2871918
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Alterations induced in distribution and in vivo metabolism of imipramine by pregnenolone-16alpha-carbonitrile.
    Brookman S; Kourounakis P
    J Pharm Sci; 1977 Oct; 66(10):1492-4. PubMed ID: 925914
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Sex-related alterations in the functional development of the thermoregulatory system of rats exposed to tricyclic antidepressants at an early age].
    Taguchi H
    Nihon Yakurigaku Zasshi; 1987 Feb; 89(2):63-72. PubMed ID: 3570104
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The effects of desipramine on thyroid hormone concentrations in rat brain.
    Campos-Barros A; Meinhold H; Köhler R; Müller F; Eravci M; Baumgartner A
    Naunyn Schmiedebergs Arch Pharmacol; 1995 May; 351(5):469-74. PubMed ID: 7643910
    [TBL] [Abstract][Full Text] [Related]  

  • 96. New metabolites of imipramine.
    Crammer JL; Scott B
    Psychopharmacologia; 1966; 8(6):461-8. PubMed ID: 4162722
    [No Abstract]   [Full Text] [Related]  

  • 97. A comparative study on desipramine pharmacokinetics in the rat brain after administration of desipramine or imipramine.
    Daniel W; Melzacka M
    J Pharm Pharmacol; 1992 May; 44(5):429-32. PubMed ID: 1359059
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Steady-state serum concentrations of imipramine, its main metabolites and clinical response in primary enuresis.
    Furlanut M; Montanari G; Benetello P; Bonin P; Schiaulini P; Pellegrino PA
    Pharmacol Res; 1989; 21(5):561-6. PubMed ID: 2594612
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Simultaneous analysis of imipramine and its metabolite desipramine in biological fluids.
    Craig JC; Gruenke LD; Nguyen TL
    J Chromatogr; 1982 Apr; 239():81-6. PubMed ID: 7096509
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effects of albumin and alpha 1-acid glycoprotein on the transport of imipramine and desipramine through the blood-brain barrier in rats.
    Lin TH; Sawada Y; Sugiyama Y; Iga T; Hanano M
    Chem Pharm Bull (Tokyo); 1987 Jan; 35(1):294-301. PubMed ID: 3594659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.